Brief India: APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka and more
In this briefing: APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka Pine Labs IPO – Building India’s Digital Checkout Future Pinelabs IPO Review - Another Fintech IPO Exactly 4yrs After Paytm - Can It Buck the Trend? L&T Finance: Building up on Early Wins. Maintain ADD Piramal Finance: Corporate Structure Simplified, Legacy Drag Diminishing. Maintain ADD 1. APAC Healthcare Weekly (November 9) – Celltrion, Dong-A ST, Hanmi Pharm, Boan Bio, Eisai, Otsuka Celltrion inlicensed two antibody-based new drug candidates for the treatment of autoimmune diseases in KRW1T deal. Dong-A ST received approval for epilepsy drug, Xcopri, developed by SK Biopharmaceuticals in Korea. Hanmi Pharmaceutical will distribute and sell three major COPD treatments developed by Boehringer Ingelheim. Shandong Boan Biotechnology’s marketing application for denosumab biosimilar has been accepted in the UK. Eisai has settled patent infringement litigation with Torrent Pharmaceuticals related to Lenvima in the U.S.